AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00907088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy milk intake
Description: In addition to the standard nutrition counselling, the intervention group will receive specific information regarding healthy milk intake (2 cups per day, maximum 16 ounces) and the potential negative health effects of prolonged bottle use and excessive milk intake including anemia, iron depletion, and dental carries.
Study NCT00907088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard nutrition counselling
Description: Parents of children will receive nutrition counselling via trained study personnel, including recommendations for iron containing food choices and timing of cow's milk introduction. This group will also receive a colourful nutrition book.
Study NCT03107000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: Incisional surgery for glaucoma
Study NCT03107000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phako-trabeculectomy
Description: Incisional surgery for glaucoma plus cataract
Study NCT02882984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib
Description: radiation given along with one of kind TKI
Study NCT02882984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib
Description: radiation given along with one of kind TKI
Study NCT02882984 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBRT
Description: 3750 cGy in 15 fractions given within 3 weeks time.
Study NCT02882984 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HFSRS
Description: All HFSRS given in 5 fractions. dose per fraction ranges from 5 to 8 Gy depending on the target volume and organs at risk tolerance.
Study NCT04411407 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order
Description: PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order
Study NCT00328809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spironolactone
Description: spironolactone administered to ESRD patients at low dose
Study NCT03694652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE
Description: Patient-centered Assessment and Counseling for Exercise \[PACE\] program
Study NCT03694652 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PACE
Description: Patient-centered Assessment and Counseling for Exercise \[PACE\] program
Study NCT03694652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Motivating healthy dietary habits
Study NCT03694652 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Motivating healthy dietary habits
Study NCT03694652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App
Description: Using an app to deliver communication to the participant.
Study NCT03694652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face
Description: Using in person meetings and/or phone communication with the participant.
Study NCT04545372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Study NCT03298100 — intervention group
Intervention type: OTHER
Intervention: Scoring model
Description: Determining risk factors an calculating the risk score, recurrent vaginal bleeding 3, hypertension 2, age and endometrial thickness 1 for each
Study NCT04465149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Third Molar Germectomy
Description: Surgical extraction of Third Molars that exhibits at least a third of its root in formation, with a periodontal ligament discernible on panoramic x-ray (defined as germectomy).
Study NCT06742242 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphaticovenous anastomosis
Description: supermicrosurgical lymphatic vessel to recipient ven lumen-to-lumen coaptation
Study NCT02622022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine hydrochloride
Study NCT03599752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive chemotherapy
Study NCT03599752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Undergo pulmonary metastasectomy
Study NCT01950351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03151798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase II: Lifestyle treatment
Description: Subjects will undergo energy restriction and exercise training over a 9 month period.
Study NCT03151798 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Phase II: Control treatment
Description: Subjects will receive dietary advice and receive information on a stretching program.
Study NCT03151798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase I: Observational studies
Description: The liver samples from patients undergoing bariatric surgery or a diagnostic liver biopsy will undergo in vitro assays to determine the capacity of the tissue to burn fat
Study NCT04594252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: Administered orally as tablets.
Study NCT04527315 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Various questionnaires will be used to assess short and long-term impacts of depression, anxiety, and other indicators of overall mental health and quality of life
Study NCT04054310 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver Multi Scan
Description: MRI to create cT1, T2\* and PDFF images of patients liver.
Study NCT02234622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holistic Yoga Program
Description: The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
Study NCT03646292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: The investigators will compare the degree of liver fat before and after pioglitazone monotherapy.
Study NCT03017989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRF imaging
Description: By using a fluorescence imaging device (with an adapted light source and camera), a fluorescent dye can be made visible. By injecting the fluorescent dye intravenously, the vascularization will be visible. Thereby, structures with altered vascularization are expected to 'light up' differently than the surrounding.
Study NCT02234622 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Lifestyle Program
Description: The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity walking with didactics about wellness topics.
Study NCT01870492 — intervention group
Intervention type: DRUG
Intervention: Activase
Description: Patients treated with Activase
Study NCT00857376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid at 3 doses compared to placebo
Description: This is a randomized study comparing the antioxidant effects of 3 doses of alpha lipoic acid (total of 600 mg daily, 1200 mg daily and 1800 mg daily) compared to placebo. These doses will be taken as 2 pills 3 times a day for 8 to 10 weeks.
Study NCT00857376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alpha lipoic acid at 3 doses compared to placebo
Description: This is a randomized study comparing the antioxidant effects of 3 doses of alpha lipoic acid (total of 600 mg daily, 1200 mg daily and 1800 mg daily) compared to placebo. These doses will be taken as 2 pills 3 times a day for 8 to 10 weeks.
Study NCT02810691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soluble fiber supplementation
Description: Two different doses of psyllium powder will be diluted in 250 ml of orange-flavored water and drink in 5 minutes before breakfast.
Study NCT02810691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for fiber supplementation)
Description: Placebo will consist of 250 ml of orange-flavored water to be drink in 5 minutes before breakfast.
Study NCT02183428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356
Study NCT02183428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1356
Study NCT01870492 — intervention group
Intervention type: DEVICE
Intervention: Endovascular therapy
Description: Patients treated with endovascular therapy, such as IA-tPA, mechanical thrombectomy, etc for acute ischemic stroke or transient ischemic attack.
Study NCT02183428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Study NCT00586690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NK Cell infusion using CD56 monoclonal antibody
Description: The cells from leukapheresis will be natural killer (NK) cell selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II acute graft versus host disease (aGVHD) at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
Study NCT00586690 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Donor Apheresis
Description: Apheresis repeated daily up to 3 days until target dose of cells reached (preferably without donor receiving growth factors). Cells were transfused immediately after collection and processing. If collections occurred during initial mobilization at the time of stem cell transplant, the donor was off growth factor for >24 hours. These extra cell collections from the donor were sufficient for the natural killer cells used in the trial. The cells were NK selected using a CD56 antibody (CliniMACS CD56 Reagent), CliniMACSplus instrument and CliniMACS tubing set provided by Miltenyi Biotec using the company protocol (Miltenyi Biotec Inc, Auburn, California). Pre and post processing cell count, viability, Hematopoietic Progenitor Cell Assay (HPCA) and flow analysis were done.
Study NCT01574781 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Description: Blood is drawn at the appropriate time given their cohort inclusion.
Study NCT02183428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Study NCT02183428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 + Glyburide
Study NCT01574781 — intervention group
Intervention type: PROCEDURE
Intervention: Cheek swab/Saliva Sampling
Description: In lieu of blood draw, male relatives may donate cheek swab or saliva sample. Children born to participating women can donate cheek swab or saliva sample soon after birth.
Study NCT03646292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: The investigators will compare the degree of liver fat before and after empagliflozin monotherapy.
Study NCT02183428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1356 + Glyburide
Study NCT01199341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: 100 mg per oral, twice daily for 14 days
Study NCT01199341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 10 x 2.5 mg per oral, once daily at day 1 and day 15
Study NCT01199341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: 4 x 100 mg per oral, twice daily for 14 days
Study NCT06655077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RA PRO Dashboard
Description: The RA PRO Dashboard was developed by UCSF rheumatology investigators in collaboration with the UCSF SOMTech Unit. Briefly, investigators used a human-centered design approach to build a new, EHR-integrated, patient-facing visualization tool that displays RA outcome data to RA patients during clinical visits. The RA PRO dashboard was tailored for deployment at the UCSF Health's rheumatology clinic using a EHR side-car application (Salesforce). The dashboard was launched into the production environment in August 2021. With the launch, investigators integrated quality improvement, user monitoring, and lean management techniques to promote use of RA outcomes and the dashboard (for clinicians granted access) during clinical visits.
Study NCT03476239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab will be supplied as single-use glass injection vials as a sterile, preservative-free, white to off-white, lyophilized powder for reconstitution and administration by continuous intravenous infusion (CIVI).~A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2 week treatment-free interval. The treatment-free interval may be prolonged by up to 7 days, if deemed necessary by the investigator.
Study NCT03476239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamthasone
Description: Premedication with dexamethasone was intended to prevent cytokine release syndrome (CRS) events associated with blinatumomab treatment. Treatment could start pre-study. Dexamethasone 20 mg IV was administered within 3 hours before start of blinatumomab in each treatment cycle, and within 3 hours before dose step increase.
Study NCT04494165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage with frankincense and myyrh essential oil
Description: In addition to the standard physical therapy session, 30 patients in aromatherapy group received a total of six sessions of lumbar massage for three weeks with frankincense and myrrh essential oils, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes. During the massage, an average of 3ml mixture prepared by adding 2% frankincense oil and 2% myrrh essential oil to jojoba carrier oil was used as an oil mixture.
Study NCT04494165 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: massage with carrier oil
Description: In addition to the standard physical therapy session, 31 patients in placebo group received a total of six sessions of lumbar massage for three weeks with jojoba oil, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes.
Study NCT00618956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran hydrochloride
Description: Milnacipran 100 to 200 mg/day tablet (administered in divided doses, twice daily \[BID\]), oral administration.
Study NCT00618956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04358250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Superior Approach
Description: GROUP II :Patients positioned in lateral decubitus.landmark for incision is the apex of the greater trochanter,and skin, subcutaneous tissue except fascia are incised accordingly. Fibers of gluteus will be separated and not incised.posterior capsulotomy is performed,;femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach. Acetabulum is prepared with burs of increasing diameter, and acetabular cup is impacted. A polyethylene insert and a femoral rasp are subsequently introduced.All remaining definitive implants can be positioned.
Study NCT04358250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterolateral approach
Description: GROUP I:patients are positioned in lateral decubitus.Landmark for incision is the apex of the greater trochanter.posterior capsulotomy is performed, femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach.Acetabulum is prepared with burs of increasing diameter,and acetabular cup is then impacted.All definitive implants can be positioned.
Study NCT01765712 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Anterior Cruciate ligament reconstruction bone patellar tendon bone autograft
Study NCT03263143 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Palliative Care
Description: Palliative Care Consultation within 24 to 48 hours after admission
Study NCT01765712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Cruciate ligament reconstruction bone patellar tendon bone autograft
Study NCT01765712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Study NCT02049567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FluidVision AIOL
Description: Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
Study NCT02049567 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: Performed using standard microsurgical techniques
Study NCT02167269 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baby EAR
Description: A modification of the Enclosed Afferent Reservoir anesthesia circuit (EAR) for pediatric use by adding a KKU one-way valve in the expiratory limb
Study NCT04371510 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Description: a blood sample is taken on Covid-19 chronic haemodialysis patients with moderate symptoms
Study NCT04387474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain-computer interface
Description: brain-computer interface rehabilitation training.
Study NCT01950351 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo proton beam radiation therapy
Study NCT01950351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02171650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Study NCT02622022 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00818909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane
Description: Systane prescription
Study NCT03646292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of pioglitazone and empagliflozin
Description: The investigators will compare the degree of liver fat before and after pioglitazone and empagliflozin combination therapy.
Study NCT02905019 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21 with Matrix-M1
Description: Vaccine
Study NCT02905019 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63 ME-TRAP
Description: Vaccine
Study NCT02905019 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA ME-TRAP
Description: Vaccine
Study NCT02102737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-DIG
Description: injection of 6-DIG
Study NCT02102737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: clamp
Description: hyperinsulinemic euglycemic clamp
Study NCT03598218 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofraction radiation
Description: Hypofractionated dose IMRT: GTVnx 60Gy, GTVnd 60Gy, PTV1 50Gy and PTV2 45Gy in 25 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles.
Study NCT03598218 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard dose IMRT
Description: Standard dose IMRT: GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 54.9Gy and PTV2 54Gy in 33 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles.
Study NCT02096133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Vitamin D3 solution
Study NCT04387474 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional rehabilitation
Description: traditional rehabilitation training.
Study NCT04387474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation
Description: traditional rehabilitation training.
Study NCT02096133 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo comparator
Study NCT00524303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 4mg/kg IV loading dose followed by 2mg/kg IV weekly
Study NCT00524303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 4mg/kg IV loading dose followed by 2mg/kg IV weekly
Study NCT00524303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80mg/m2 IV weekly for 4 (21 day) cycles
Study NCT00524303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m2 IV weekly for 4 (21 day) cycles
Study NCT00524303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FEC75
Description: 5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles
Study NCT00524303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC75
Description: 5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles